SRRK 주가 차트
SRRK 재무
Scholar Rock Holding Corp
$49.19
3.92%
$1.85
종가: Jun 22, 16:00:00 GMT-4
$48.85
-0.69%
$-0.33
프리마켓: Jun 23, 07:36:13 GMT-4
뒤로
Scholar Rock Holding Corp (SRRK) 재무
주요 통계
이전 종가
$47.33
시가
$47.95
일일 범위
$47.73 - $49.82
52주 범위
$27.07 - $52.18
거래량
1.5M
평균 거래량
1.3M
배당수익률
--
EPS(TTM)
-3.45
시가총액
$5.8B
SRRK란 무엇인가요?
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The firm focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
